When the president of a cancer-fighting foundation implored government advisers to back the drug Tarceva as a treatment for pancreatic cancer, she didn't tell them its Long Island manufacturer had given thousands of dollars to her group.
Instead, Carolyn Aldige of the Cancer Research and Prevention Foundation told a Food and Drug Administration advisory committee she had no financial ties to OSI Pharmaceuticals, the Melville company that makes Tarceva.
But Aldige now says her foundation had received funding from OSI and its marketing partner for Tarceva, Genentech.